Trial Profile
CTT1057, a Small Molecular Inhibitor of Prostate Specific Membrane Antigen (PSMA), as a Novel Imaging Agent of Neovascularization in Renal Cell Carcinoma (RCC): A Pilot Study
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs 18F-CTT 1057 (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions
- 19 Apr 2019 Status changed from recruiting to completed.
- 16 Jul 2018 Planned primary completion date changed from 1 Jun 2018 to 31 Aug 2018.
- 12 Feb 2018 New trial record